250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in France in January 2025

A list of 50 VC (Venture Capital) funds that invest in Life science startups based in France. We rank investors based on the number of investments they made in Life science companies from France. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in France in January 2025

Investor Life Science France investments
Bpifrance 12
Kurma Partners 8
Omnes Capital 6
Seventure Partners 5
Idinvest Partners 4
Paca Investissement 4
Galia Gestion 3
Boehringer Ingelheim Venture Fund 3
Blue Horizon Corporation 3
Sofinnova Partners 3
AdBio partners 3
Karista 3
Partech 2
WiSEED 2
XAnge 2
AQUITI Gestion 2
Kinled Holding 2
Horizons Ventures 2
Social Starts 2
Sofimac Investment Managers 2
Eutopia VC 2
Beyond Impact 2
Point Nine 2
Heartcore Capital 2
Siparex Groupe 2
Advent Life Sciences 2
Thia Ventures 2
IRDI SORIDEC Gestion 2
JDRF T1D Fund 2
Air Street Capital 2
Credit Mutuel 1
Polytechnique Ventures 1
Capital Grand Est 1
Banexi Ventures 1
Roche Venture Fund 1
Eurobail 1
MACSF 1
Sudinnova 1
IXO Private Equity 1
Shire 1
Thai Union Ventures 1
INRA 1
Angels Santé 1
AxLR 1
Resonance 1
Lundbeckfonden Ventures 1
ACT Venture Partners 1
Eternam 1
Earlybird Venture Capital 1
Afone Participations 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Bpifrance VC Fund · Maisons-alfort, Ile-de-France, France · 89 investments in the past 12 months
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Funding Round, Series A
  • France, United States, Switzerland
Portfolio highlights
  • Vibly — Vibly is a comprehensive management and communication platform designed to support higher education associations by enhancing organizational efficiency, increasing the visibility of student initiatives, and fostering a stronger sense of belonging within educational communities. Through its secure, closed network, Vibly ensures the protection ofprivate data while facilitating seamless interaction and collaboration among students, faculty, and associations.
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • NEBULA — NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.
Kurma Partners VC Fund · Paris, Ile-de-France, France · 9 investments in the past 12 months
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
  • Health Care, Biotechnology, Pharmaceutical
  • Series A, Seed, Series B
  • France, Switzerland, Spain
Portfolio highlights
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • Omnidoc — Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.
  • Raidium — Radiology augmented GPT to tackle the complexity of precision medicine
Omnes Capital VC Fund · Paris, Ile-de-France, France · 8 investments in the past 12 months
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more
Investment focus
  • Biotechnology, Software, Health Care
  • Series A, Funding Round, Series B
  • France, Germany, United States
Portfolio highlights
  • Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • The Exploration Company — For Space & Non-Space Industries.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 15 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Series A, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
  • Syroco — Syroco is a Climate Tech startup that supports the energy transition of maritime transportation. It provides a solution for weather routing and voyage optimisation of commercial vessels, leveraging digital twins based on data and AI.
  • bsport solution — Designed to support all facets of studio management, our software allows studio owners and managers to streamline and centralise all their operations into one user-friendly platform.
Idinvest Partners VC Fund · Paris, Ile-de-France, France
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Series B, Series A, Funding Round
  • France, United States, Spain
Portfolio highlights
  • Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability
Paca Investissement VC Fund · Paris, Ile-de-France, France
Paca Investissement is specializes in investing in startups and developmental stages. The fund invests in the Provence-Alpes-Côte d'Azur (PACA) region.
Show more
Investment focus
  • Software, Internet, Manufacturing
  • Seed, Funding Round, Series A
  • France
Portfolio highlights
  • GANGZ — Gangz is the first digital platform for talent recruitment: Models, hosts, extras and actors.
  • SailEazy — The SailEazy community offers all sailing enthusiasts the choice of freedom. A shared professional fleet, bases between the Atlantic and the Mediterranean ... discover a disruptive and innovative way of navigation. Throughout the year, 7 days / 7 and 24 hours a day, you can book and discover the high-performance sailboats of a professionalfleet, entirely managed by SailEazy. Subscriber, or punctual browser, autonomous or not, you have the choice. You freely determine your niche of reservation, without constraint time or duration, you choose your base of departure and your sailboat, according to your program (short exit, cruise, regatta, coastal, wide ...). Hourly pricing includes a 360 ° service keychain beyond the cost of the lease, including insurance, fuel, cleaning and equipment. Compulsive veiled, expert or contemplative, all members of the community have their way of navigating.
  • C4Diagnostics — C4Diagnostics developed a fast, reliable detection of microorganisms. Our Click-chemistry technology is at the core of our portfolio of diagnostic tests.
Galia Gestion VC Fund · Bordeaux, Aquitaine, France
Galia Gestion is a private equity and venture capital firm. GALIA Gestion is a “management company” approved by the AMF, with majority shareholder Alliance Entreprendre.
Show more
Investment focus
  • Software, Manufacturing, Biotechnology
  • Funding Round, Series A, Seed
  • France, United States
Portfolio highlights
  • Wizaly — Wizaly's ambition is to help advertisers understand the impact of their online & offline marketing channels across all conversions, helping clients improve the ROI of their marketing budgets by up to 30%.The Wizaly platform applies its algorithmic attribution technology to provide a holistic and unbiased vision of campaigns performancestogether with actionable optimization recommendations.
  • Agenium — Agenium offers career perspectives in an international and tech environment. They offer this through the specific expertise of their business units. They offer solutions to the business and of the defense, industry, and space sectors.
  • Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 2 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
  • Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
  • Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.
Blue Horizon Corporation VC Fund · Zürich, Zurich, Switzerland
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more
Investment focus
  • Food and Beverage, Food Processing, Biotechnology
  • Seed, Series A, Funding Round
  • United States, United Kingdom, France
Portfolio highlights
  • WOW EARN — WOW EARN connects users to the blockchain, enabling them to mine, earn, and trade via decentralised mining, earning, and trading systems.
  • foodforecast — AI supported solution to reduce food waste.
  • New School Foods — Whole-muscle, plant-based seafood
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 23 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
  • Noema Pharma — BEYOND SYMPTOM CONTROL Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their li ...
  • Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
AdBio partners VC Fund · Paris, Ile-de-France, France · 2 investments in the past 12 months
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Seed, Series A, Funding Round
  • France, Spain, Belgium
Portfolio highlights
  • Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
  • Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
  • Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases
Karista VC Fund · Paris, Ile-de-France, France · 7 investments in the past 12 months
Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Seed, Series A, Series B
  • France, United States, Finland
Portfolio highlights
  • Deemea — Deemea is a collaborative AI platform that connects and provides services for the analysis of medical data for physicians. It uses its expertise in clinical research, data science, and software development to help healthcare professionals.
  • 10Lines — 10Lines is developing autonomous parking lot marking robots and technological solutions to significantly increase productivity in the industry of pavement marking. Our solutions are helping striping businesses do their work much more productively with a smaller environmental footprint.
  • Brightflow — Brightflow operates as a medical device startup.
Partech VC Fund · Paris, Ile-de-France, France · 21 investments in the past 12 months
Partech is a global venture capital firm with offices in San Francisco, Paris, Berlin and Dakar. Partech invests in Internet and information technology startups at seed, venture and growth stages.
Show more
Investment focus
  • Software, E-Commerce, SaaS
  • Series A, Seed, Series B
  • United States, France, Germany
Portfolio highlights
  • KoRo — KoRo is a fast-growing FoodTech startup - one of the leading brands for healthy, long-lasting and sustainable food.
  • Yampa — Discover yampa's autonomous AI agents and revolutionize your customer experience. Elevate your service with the most advanced AI technology.
  • Socium — Socium Job these are companies that recruit and offer real career opportunities to all those who share their values ​​and wish to invest in their development.
WiSEED VC Fund · Toulouse, Midi-Pyrenees, France · 2 investments in the past 12 months
Wiseed is a crowdfunding platform that enables its users to invest in SMEs and enterprises. The platform offers investments for startups, real-estate firms, social innovation and renewable energy projects, and agriculture firms. It was founded in 2008 by Nicolas Seres and Thomas Merquiol and is based in Toulouse.
Show more
Investment focus
  • Software, Manufacturing, Biotechnology
  • Seed, Funding Round, Equity Crowdfunding
  • France
Portfolio highlights
  • Leasi — Leasi delivers a forward-thinking rental and resource management system for companies that engage in internal or external distribution of machinery. This is achieved through an ecosystem that emphasizes the excessive use of data and datasharing, with a focus on user experience. Our goal is to create a simpler, more streamlined, and more efficientworkday for industry players by leveraging the power of data and collaboration within the ecosystem to ultimately reduce emissions, increase efficiency and enhance profitability.
  • Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
  • BiPER Therapeutics — BiPER Therapeutics : First-In-Class Therapeutics to Treat Cancer. Biotech company founded in 2021 to develop and commercialize novel therapeutics.
XAnge VC Fund · Paris, Ile-de-France, France · 6 investments in the past 12 months
For 20 years, XAnge has been a key venture capital fund in Europe. With 70 startups in its portfolio, XAnge invests early in innovative tech companies.
Show more
Investment focus
  • Software, Information Technology, SaaS
  • Series A, Seed, Series B
  • France, Germany, Belgium
Portfolio highlights
  • TEEPTRAK — Optimise your industrial efficiency with TeepTrak. Improve your production and exceed your objectives today!
  • Gladia.io — 1 stop shop AI API hub for developers
  • SamanTree Medical — SamanTree Medical has developed the Histolog Scanner, a confocal microscopy device intended for imaging the surface of excised human tissue specimens to visualize morphological microstructures. Easy-to-read images are available immediately, providing decision-making support at the point of care.
AQUITI Gestion VC Fund · Bordeaux, Aquitaine, France · 2 investments in the past 12 months
Floated in 1998, thanks to the local authority "Conseil Régional d’Aquitaine" and the "Caisse des dépôts", our venture, growth and LBO funds (Aquitaine Amorçage, ACI, Aqui-Invest) now benefit from the support of public and private influential shareholders and sponsors.Up to now, AQUITI GESTION has invested in more than 200operations contributing to the creation and development of about 150 companies and thousands of jobs.Currently, ACI and Aqui-Invest manage a portfolio gathering 50 companies which revenues scale from 0 € (early stage) to 30 M€.
Show more
Investment focus
  • Biotechnology, Software, Health Care
  • Funding Round, Series A, Seed
  • France, United States
Portfolio highlights
  • Dionymer — dionymer creates endless opportunities for a multitude of industries. Replacing petrochemical polymers with a circular and biodegradable alternative.
  • Materrup — Materrup produces low-carbon earth concrete for construction and urban development. Materrup construction solutions meet the requirements of future RE2020 regulations and the urgent need to reduce the carbon footprint of the construction industry.
  • ALOGIA Groupe — ALOGIA Groupe offers preventive health responses to senior people at home through care management and innovative services.
Kinled Holding VC Fund · New York, New York, United States
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more
Investment focus
  • Biotechnology, Health Care, Financial Services
  • Seed, Funding Round, Series A
  • United Kingdom, United States, Switzerland
Portfolio highlights
  • Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
  • OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
  • Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.
Horizons Ventures VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 12 investments in the past 12 months
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
  • Biotechnology, Artificial Intelligence, Software
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
  • ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
  • Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
Social Starts VC Fund · San Francisco, California, United States
Social Starts is a $60M+ venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Seed, Series A, Funding Round
  • United States, Germany, United Kingdom
Portfolio highlights
  • Hey Jane — Get safe, effective and affordable abortion pills delivered fast to your home. Hey Jane is the first digital abortion clinic, connecting you to licensed providers in your state through telemedicine.
  • Mae Health — Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes.
  • Wayfinder Biosciences — We design RNA for next generation biomanufacturing and smart therapeutics.
Sofimac Investment Managers VC Fund · Clermont-ferrand, Auvergne, France
Acteur incontournable du capital risque de proximité, SOFIMAC PARTNERS accompagne depuis maintenant plus de 30 ans les PME régionales dans le financement de leur développement à moyen / long terme. Répondant à la problématique de sous capitalisation des PME françaises, SOFIMAC PARTNERS intervient en fonds propres aux côtés des chefsd’entreprises quelle que soit leur problématique : Création, Développement, Transmission. Gérant 200 M€ d’actifs au travers de 16 fonds (FCPR, FCPI, SCR, FIP,…), notre groupe réalise ses investissements sur une grande variété de secteurs, couvrant aussi bien les activités traditionnelles que technologiques (chimie verte, éolien, chaudronnerie aéronautique, e-commerce, édition de logiciel, médecine nucléaire etc…)
Show more
Investment focus
  • Biotechnology, Health Care, Manufacturing
  • Funding Round, Seed, Series A
  • France, Italy, Austria
Portfolio highlights
  • Ultrawatt — Ultrawatt is a mission-driven startup to improve urban architecture while making a beneficial social and environmental effect.
  • Mob-Energy — Mob-Energy is a privately held company specializing in the development of mobile and innovative charging solutions. It designs autonomous charging robots capable of moving energy where it is needed, optimizing the site's existing infrastructure. The company was founded in 2018 and is headquartered in Villeurbanne, Auvergne-Rhône-Alpes.
  • Snowleader — Votre boutique en ligne (qui sent bon le reblochon) spécialiste des sports d’hiver, outdoor et street.
Eutopia VC VC Fund · Paris, Ile-de-France, France
Eutopia is a fund for consumer startups. We back founders who are rethinking the way we eat, shop, sleep and feel. We are backing 26 startups
Show more
Investment focus
  • Retail, E-Commerce, Food and Beverage
  • Seed, Series A, Funding Round
  • France, Belgium, Denmark
Portfolio highlights
  • GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
  • Bastille — Bastille is a brand of urban bicycles. The Astir brand is synonymous with folding bicycles. The primary quality constraint Bastille, a British designer, aims to create a folding motorcycle with standard wheels rather than the mini 16-inch wheels that are traditionally associated with folding bikes.
  • Nous anti-gaspi — We anti-Gapsi is the network of anti-waste food stores. This grocery store project offers producers and manufacturers the opportunity to their downgraded and unsold products at a fair price. They are a qualitative environment, they market products excluded from the usual mass distribution circuits for small defects, physical defects, contract-datenot respected, and end of series. They offer consumers a new mode of consumption that gives priority to common sense and that is at the same time smart, qualitative, and eco-responsible. In their stores, they offer you to find, in a warm atmosphere, a complete choice of food products to save waste: fruits and vegetables, fresh and frozen products, groceries, and even a small bulk section.
Beyond Impact VC Fund · Minneapolis, Minnesota, United States
Beyond Impact is your trusted Managed Service Provider (MSP), delivering tailored IT solutions like managed IT services, cybersecurity, cloud computing, IT help desk support, and data backup. Our expert team aligns your IT with business goals, providing proactive monitoring and network security. Contact us today to streamline your IT operations for a secure, agile, and future-ready business. Beyond Impact: Empowering your IT success.
Show more
Investment focus
  • Food and Beverage, News, Seafood
  • Seed, Series A, Pre-Seed
  • France, Canada, Singapore
Portfolio highlights
  • GOURMEY — We create sustainable cultivated meat delights for an uncompromising and conscious generation.
  • Nowadays — The Nowadays nugget is made with just 7 simple, plant-based ingredients.
  • SEAFOOD REBOOT — Seafood Reboot's ambition is to promote worldwide best-in-class Fish substitutes from micro-algae for natural, healthy, sustainable food and to preserve marine wildlife.
Point Nine VC Fund · Berlin, Berlin, Germany · 9 investments in the past 12 months
Point Nine Capital is a Berlin-based venture capital firm focused exclusively on early-stage Internet investments in areas like Software-as-a-Service (SaaS), online marketplaces, and mobile.The fund and its managers, Pawel Chudzinski and Christoph Janz have backed a number of highly successful Internet companies such as Delivery Hero, Clio,Shiftplanning, Vend, Typeform, and Zendesk from their earliest stages.
Show more
Investment focus
  • Software, SaaS, Internet
  • Seed, Series A, Series B
  • Germany, United States, France
Portfolio highlights
  • Attio — Unlock your team's true potential with Attio, the data-driven CRM for modern teams. Manage everything from sales leads through to recruitment pipelines.
  • Hula Earth — Biodiversity Monitoring for Nature, Agriculture, and Infrastructure
  • Root Global — We help companies along the agricultural supply chain get to Net Zero.
Heartcore Capital VC Fund · Copenhagen, Hovedstaden, Denmark · 17 investments in the past 12 months
Heartcore Capital invests in companies re-enchanting the world through technology.
Show more
Investment focus
  • Software, FinTech, Artificial Intelligence
  • Seed, Series A, Series B
  • Denmark, United States, Germany
Portfolio highlights
  • Luca — Luca's learning platform provides learning programs for primary and secondary school students. The learning platform offers pre-recorded K12 videos, gamified content and AI powered personalized study paths, covering the entire official academic curriculum and national exams prep. Luca is a VC backed startup with HQ in Madrid & MexicoCity
  • Barter — Barter enables decentralized applications by ensuring efficient transaction routing and optimization.
  • Superform Labs — THE UNIVERSAL INTERFACE FOR YIELD IS FORMING
Siparex Groupe VC Fund · Paris, Ile-de-France, France
Siparex, France,s first multi-sectoral private equity investment company, is founded in Lyon.It was a start-up at a time when the spirit of enterprise was flagging. It emerged in one of France's regions, listed the shares of the original company one of its main vehicles on the stock market, grew internationally, and has become one of theindependent groups in its line of business in the space of 30 years.
Show more
Investment focus
  • Manufacturing, Software, Information Technology
  • Private Equity, Funding Round, Seed
  • France, United States, Italy
Portfolio highlights
  • E-Recycle — E-Recycle is an online and offline store that specializes in recycling used high-tech products such as mobile phones, tablets, and PCs.
  • NeoPhotonics — NeoPhotonics design and manufacture advanced hybrid photonic integrated optoelectronic devices for ultra-fast communications networks, including optical components
  • Monet Associes — Monet + Associes is a public relations agency.
Advent Life Sciences VC Fund · London, England, United Kingdom · 2 investments in the past 12 months
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Funding Round, Series B
  • United States, United Kingdom, France
Portfolio highlights
  • Argá Medtech — Novel Sine Wave Technology Promises Significant Advantages Over Existing Pulsed Field Cardiac Ablation Systems
  • PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
  • Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Thia Ventures VC Fund · Genève, Geneve, Switzerland · 3 investments in the past 12 months
WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more
Investment focus
  • Biotechnology, Food and Beverage, Health Care
  • Series A, Seed, Series B
  • United States, France, Denmark
Portfolio highlights
  • EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
  • Protealis — Sustainable plant proteins for Europe​
  • Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.
IRDI SORIDEC Gestion VC Fund · Toulouse, Midi-Pyrenees, France · 6 investments in the past 12 months
IRDI SORIDEC Gestion is a portfolio management company that supports startups, SMEs, and ETIs in the greater South-West of France with equity capital at all stages of development.
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Seed, Series A, Funding Round
  • France, Brazil, Singapore
Portfolio highlights
  • IsyBuy — IsyBuy is a smartphone application that allows to find restaurants and bars that have your way, consult the menu, place order, and still pay your bill directly from your cell phone, with just one click. It's the fastest, easiest, and safest way to borrow and pay. They will never have to wait to be served by a waiter, let alone beg to receivethe account or the card machine.
  • Keysom — Keysom is a French startup expert in the architecture of processor cores based on the RISC-V ISA. Keysom offers ad EDA tool to automatically build unique custom processors from the application code.
  • Materrup — Materrup produces low-carbon earth concrete for construction and urban development. Materrup construction solutions meet the requirements of future RE2020 regulations and the urgent need to reduce the carbon footprint of the construction industry.
JDRF T1D Fund VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Funding Round, Series B
  • United States, France, Italy
Portfolio highlights
  • vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
  • Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
  • Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...
Air Street Capital VC Fund · London, England, United Kingdom · 6 investments in the past 12 months
Air Street Capital invests in AI-first companies.
Show more
Investment focus
  • Artificial Intelligence, Machine Learning, Biotechnology
  • Seed, Series A, Pre-Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Odyssey — The next frontier of artificial intelligence: generative world models.
  • Profluent Bio — Profluent Bio is an AI-first protein design company that designs novel, optimal proteins that bypass existing barriers in industry.
  • Interloom Technologies — Interloom offers AI-driven process automation for enterprises to maximize organizational efficiency and accuracy.
Credit Mutuel VC Fund · Strasbourg, Alsace, France · 2 investments in the past 12 months
Credit Mutuel is a French investment bank specialized in early stage venture investments.
Show more
Investment focus
  • Finance, Financial Services, E-Commerce
  • Funding Round, Series A, Seed
  • France
Portfolio highlights
  • Hipli — Hipli is a reusable, eco-friendly packaging solution that offers a sustainable alternative to plastic packaging for e-commerce businesses.
  • Vinidaily — Vinidaily is the application that helps you choose the wine 100% adapted to your tastes and the occasion, in your favorite supermarket and soon everywhere else.
  • Agrilife Studio — Agrilife Studio is a startup studio focuses on agriculture and environment.
Polytechnique Ventures VC Fund · Paris, Ile-de-France, France · 5 investments in the past 12 months
Polytechnique Ventures support entrepreneurs from the School's ecosystem.
Show more
Investment focus
  • Energy, Renewable Energy, Apps
  • Seed, Pre-Seed, Funding Round
  • France, United Kingdom
Portfolio highlights
  • Airthium — Airthium builds a new kind of energy storage system, that stores electricity as heat - reversibly - and in the form of ammonia.The system relies on a high-temperature heat pump/heat engine to heat molten salt to 540°C ( 1000°F), and then convert the heat back into electricity, with a 70% roundtrip efficiency.Airthium's units can beused to store and deliver solar and wind energy, starting at 100 kW and up to GW scale (Utility).Moreover, an ammonia generation unit and an external ammonia burner can be added to the system, to provide uninterruptible power, or go off-grid, even after several days of bad weather (no sun/wind).
  • PACT — PACT designs Elegant materials produced in tune with the planet earth. It create revolutionary, sustainable biomaterials using the earth's resources, including collagen, herbal extracts, oils, and minerals.
  • Descartes & Mauss — The first AI-powered SaaS Platform automating the Strategic Planning process.
Capital Grand Est VC Fund · Schiltigheim, Alsace, France
Capital Grand Est is a private equity firm that focuses on supporting businesses. Capital Grand Est was founded in 2012 and was headquartered in Schiltigheim, France.
Show more
Investment focus
  • Health Care, Biotechnology, Computer
  • Funding Round, Seed, Series A
  • France
Portfolio highlights
  • Braintale — Braintale develops and distributes accessible and effective diagnosis and prognosis tools for brain-injured patients.BrainTale’s products are based on medical needs understanding, fulfilling healthcare professionals and patients’ expectations, and is built upon more than 15 years of clinical development. The company was founded in 2018 and basedin Paris, France.
  • Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.
  • Sirfull Technology — Solutions SIRFULL pour le soudage, l'inspection et la maintenance | Welding cloud logiciel soudage | Linspec Cloud logiciel inspection
Banexi Ventures VC Fund · Paris, Ile-de-France, France
Banexi Ventures Partners invests through venture capital funds, in early stage companies with high growth potential and high technology in 3 different sectors. The company is headquartered in Paris, France.
Show more
Investment focus
  • Mobile, Internet, Video
  • Series B, Series A, Funding Round
  • France, United States, United Kingdom
Portfolio highlights
  • Dolmen — Dolmen is an all-in-one platform to answer your many customer knowledge issues. Dolmen is the SAAS software solution to deploy in physical outlets and in your marketing departments. In local to animate, conquer and retain your customers. Central to enrich your databases and allow your network to communicate autonomously while driving your marketingactions.
  • Reevoo — Millions of shoppers use Reevoo to make better buying decisions in their everyday lives. Hundreds of brands all over the world use our solutions to get a better idea of what makes their customers tick.It’s our transparent and independent approach that makes the difference – we believe honest communication between brand and shopper is better forboth.Reevoo was started by Richard Anson, Ben Griffiths and Guy Logan in 2005 to help customers choose what to buy – not just where or when.Today, Reevoo is seen in more than 60 countries and in 30 different languages. We’re relied on by customers around the world to make better decisions, and by brands to connect with their customers.
  • Linkfluence — Linkfluence is a consumer insights platform that combines social media data, AI, and human market research expertise to uncover high-value insights..
Roche Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Spain
Portfolio highlights
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
  • Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Eurobail VC Fund · Paris, Ile-de-France, France
Eurobail is a specialized training company that works in the real estate, banking, and insurance industries.
Show more
Investment focus
  • Health Care, Life Science, Clinical Trials
  • Series A
  • France
Portfolio highlights
  • DocCity — DocCity LifeSciences creates and provides outstanding spaces to house cutting-edge healthcare businesses. DocCity provides clinicians with state-of-the-art, fully furnished health spaces with roomy, well-lit, and digitally equipped consultation rooms and reception areas.
MACSF VC Fund · La Défense, Ile-de-France, France · 2 investments in the past 12 months
Mutuelle d'Assurance du Corps de Santé Français (MACSF) is the provider of insurance to health professionals. MACSF protects and accompanies 950,000 members of all medical and paramedical specialties, offering professional and personal solutions in insurance, savings, financing, and pensions. Its products and services meet the real needs ofits members by accompanying them in the evolution of their profession and their projects.MACSF was founded in 1935.
Show more
Investment focus
  • Health Care, Artificial Intelligence, Medical Device
  • Series A, Funding Round, Seed
  • France, Spain, Ecuador
Portfolio highlights
  • Pixmania — Pixmania is an e-commerce website that provides buying and selling of speakers, cameras, headphones, and mobile devices.
  • Singulier — The new guard of strategy firm
  • RDS — RDS is a healthcare technology startup that specializes in remote patient monitoring solutions. The company's primary product, MultiSense®, is designed to help healthcare professionals continuously monitor patients' physiological parameters, whether they're in a hospital or at home. This innovative and multi-patented technology isaimed at improving patient pathways, which in turn enhances the quality of life and care efficiencies. The company's market is primarily hospitals (particularly surgical departments) and institutions that are looking for ways to improve patient care and reduce hospital stays. By facilitating early hospital discharge and continuous monitoring, RDS solution can contribute to significant healthcare savings. The MultiSense® solution is now CE marked (MDR) and is available for sale in several European countries. The company generates recurring revenues by providing the solution on a “fee for a service” business model to healthcare institutions and professionals. The product has been well-received in the market, earning multiple awards and the support of a vibrant community of clinicians. In addition to its primary product, RDS also provides services that help healthcare systems become more attractive and sustainable. This includes training and support for healthcare professionals to effectively use the MultiSense® technology. Keywords: Healthcare Technology, Remote Patient Monitoring, MultiSense®, Patient Pathways, Care Efficiencies, Hospital Discharge, Healthcare Savings, Clinicians, Physiological Parameters, Our main product, MultiSense®, is a comprehensive Remote Patient Monitoring Solution. MultiSense® offers healthcare professionals a high-precision, multi-parametric solution to continuously monitor patients’ physiological parameters in the hospital and beyond. MultiSense® combines a wearable patient monitor designed to capture high-accuracy physiological data with a cloud platform that helps transform these data into actionable clinical insights. MultiSense® is a patented medical device that has received multiple awards. MultiSense® has been validated by 6 completed clinical investigations.RDS relies on a talented and international team with deep subject-matter-expertise and a proven track record in the Healthcare and Medical Device sector. At RDS, we all share the same passion for bringing patient pathways to the next level.
Sudinnova VC Fund · Lyon, Rhone-Alpes, France
Sudinnova is a venture capital firm that invests in information technology, electronics, life sciences, and clean technology sectors.
Show more
Investment focus
  • Software, Biotechnology, Medical
  • Funding Round, Series A, Seed
  • France
Portfolio highlights
  • Kerlink — Founded in 2004, Kerlink is a fast-growing, global and publicly traded provider of Internet of Things (IoT) infrastructure, software and services serving telecom operators, public authorities and businesses of all sizes to design, launch and operate IoT networks.Anticipating a booming market for communication solutions dedicated to connecteddevices, Kerlink founders – William Gouesbet, chairman and CEO, and Yannick Delibie, deputy CEO and CTIO – foresaw the role that RF communication technologies and their associated support platforms could play in M2M vertical segments like fleet management, metering and freight.A co-founder and board member of the LoRa Alliance, Kerlink specialises in end-to-end IoT network solutions for LoRaWAN cost-effective, energy-efficient and long-distance connectivity. The company designed the world’s first commercially available product range of outdoor carrier-grade for IoT dedicated networks.Kerlink also has continuously launched a range of embedded & ruggedized devices and applications for transportation using cellular connectivity, in addition to fleet management and tracking solutions, such as passenger information and entertainment, fuel-efficiency monitoring and car/bike sharing.
  • Lucibel — Lucibel is an innovative French group that designs and manufactures new-generation lighting products and solutions in France based on LED technology. LED technology is cost efficient, sustainable and smart. It is transforming the world and is now part of the digital era. Not only are Lucibel lighting solutions compatible with remote managementsystems. Light can now interact with its surroundings and be controlled and measured in real time. But it also allows for a new medium for data transmission, interactions and well-being thanks to the development by Lucibel of innovative and smart solutions.
  • Universign — Have your PDF documents signed online with Universign: the electronic signature and timestamping service recognised by Adobe Reader.
IXO Private Equity VC Fund · Toulouse, Midi-Pyrenees, France · 7 investments in the past 12 months
The private equity fund focused on adding high value.IXO Private Equity is a private equity management company recognized, approved and authorized by the Financial Market Authorities (AMF) operating under the number GP03018.IXO Private Equity is the most important independent regional private equity General Partner in France.The companymanages French General Private Equity Investment Funds (known in France as F.C.P.R.), Local Private Equity Investment Fund (known in France as F.I.P.), and Private Equity Investment Funds for Innovation (F.C.P.I.) to meet the equity needs for the best companies in Western and Southern France.
Show more
Investment focus
  • Health Care, Manufacturing, Biotechnology
  • Private Equity, Funding Round, Series A
  • France, United States, Canada
Portfolio highlights
  • F-Reg — F-Reg autonomous and intelligent hydraulic valves are designed to regulate and control flow patterns in sanitation networks. F-Reg sells solutions for regulating flow in networks (rainwater or wastewater) that rely on a patented valve that smooths out peaks in wet weather. The F-Reg device is self-contained and does not require power.
  • Indy — Indy offers end-to-end and advanced AI-powered accounting software. Indy is an accounting robot that aims to automate the accounting of freelancers and professionals. It is an accounting robot for the liberal professions. It automates the management of accounting, recovers bank entries to turn them into accounting lines, and sends tax returnsdirectly to an AGM.It was founded in 2016 as Georges by Côme Fouques, Pablo Larvor, Romain Koenig, and Adrien Plat to simplify independent accounting, which is certainly simple but repetitive and time-consuming.
  • Farmitoo — Farmitoo is an online purchase of farm equipment directly from manufacturers.
Shire VC Fund · Dublin, Dublin, Ireland
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.
Show more
Investment focus
  • Biotechnology, Therapeutics, Biopharma
  • Series C, Series B, Series A
  • United States, France, Belgium
Portfolio highlights
  • Naurex — Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.
  • Rani Therapeutics — Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replacesubcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage.
  • Promethera Biosciences — Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way usingallogenic progenitor cells from healthy human livers.Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Thai Union Ventures VC Fund · Samut Sakhon, Samut Sakhon, Thailand
Thai Union Ventures is a corporate venture arm of thai union group.
Show more
Investment focus
  • Life Science, Biotechnology, Food Processing
  • Series A
  • France
Portfolio highlights
  • Algama — Algama harvests the potential of algae to create food that's good for both people and the planet.
INRA VC Fund · Paris, Ile-de-France, France
INRA is Europe’s top agricultural research institute and the world’s number two centre for the agricultural sciences. Its scientists are working towards solutions for society’s major challenges.
Show more
Investment focus
  • Biopharma, Health Care, Biotechnology
  • Seed, Series A
  • France
Portfolio highlights
  • ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
  • Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.
Angels Santé VC Fund · Puteaux, Ile-de-France, France
Angels Santé is a networking site for investors and companies in the health sector.
Show more
Investment focus
  • Health Care, Biotechnology, Medical Device
  • Seed, Funding Round, Angel
  • France, India, United States
Portfolio highlights
  • Abcely — Abcely is a biotech firm that is working on a novel anti-cancer medication.
  • Odimma — Empowering personalized immunotherapy to treat cancer
  • SeaBeLife — SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.
AxLR VC Fund · Montpellier, Languedoc-Roussillon, France
AxLR specializes in the assistance of commercialization and academic research maturity-based innovative projects.
Show more
Investment focus
  • Life Science, Biotechnology
  • Pre-Seed
  • France
Portfolio highlights
  • Ingraalys — Ingraalys studies genomic and cellular plasticity during development and aging. Exploring the limitations of this plasticity prompted her to investigate the potential reversibility of cellular aging.
Resonance VC Fund · Paris, Ile-de-France, France · 2 investments in the past 12 months
We are on your frequency - Resonance partners with early-stage founders, helping them to shake up their industry.
Show more
Investment focus
  • Software, Information Services, B2C
  • Series A, Pre-Seed, Seed
  • France, United Kingdom, United Arab Emirates
Portfolio highlights
  • ZELIQ — ZELIQ converts leads into clients with 450+ million contacts, finds emails and phone numbers of prospects, and automates omnichannel outreach sequences.
  • Tomorro — Leeway helps you reduce the time spent on contract management and gives you more control and visibility over legal and financial risks.
  • Okomera — Automated 3D model drug testing of cancer biopsies prior to treatment. For precision and personalized medicine. The "test before you treat" solution for every oncologist and patient.
Lundbeckfonden Ventures VC Fund · Copenhagen, Hovedstaden, Denmark
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, France
Portfolio highlights
  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
  • LEXEO Therapeutics — LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
ACT Venture Partners VC Fund · Amsterdam, Noord-Holland, The Netherlands · 4 investments in the past 12 months
Early stage deep tech investor
Show more
Investment focus
  • Artificial Intelligence, Software, Manufacturing
  • Seed, Convertible Note, Series A
  • Turkey, United States, United Kingdom
Portfolio highlights
  • Nextmol — Nextmol is your partner to accelerate chemicals discovery. Reduce time-to-market and get key insights about the behavior of your chemical molecules!
  • Qubitrium — Explore innovative quantum solutions at Qubitrium. Elevate your journey with cutting-edge products, services, and trainings. Your quantum future...
  • Meddenovo Drug Design — Meddenovo is at the forefront of AI-driven drug discovery, pioneering a specialized technology platform designed specifically for cyclic peptides. Our innovative approach leverages a unique blend of AI technologies and molecular modeling to significantly enhance the efficiency and success rates of drug development processes. Cyclic peptidesrepresent a groundbreaking class of compounds in pharmaceutical research. These molecules combine the best attributes of small molecules and large biologics, offering exceptional binding affinities, stability, and specificity. At Meddenovo, we are leaders in harnessing the potential of cyclic peptides, developing tailored solutions that push the boundaries of traditional drug discovery. Beyond small organic molecules, our expertise extends to peptide-based medicines and metal chelators, giving us a competitive edge in novel drug research and development. We excel in creating unique chemical spaces tailored to your needs and provide custom computational solutions for predicting drug resistance, elucidating biochemical reaction mechanisms, and conducting metal affinity analysis. At Meddenovo, we are dedicated to precision and reliability in drug discovery. Our approach reduces failure rates and improves outcomes, accelerating the journey from research to market. Our mission is to empower scientists worldwide with advanced, user-friendly AI tools, democratizing access to cutting-edge drug discovery technologies.
Eternam VC Fund · Paris, Ile-de-France, France
Eternam engages in business throughout the commercial real estate value chain, including investments in residential plots, club deals, SCPI allocation guidance, and real estate investment funds. They are specialists in club negotiations, capital invested in real estate, and the structuring of company real estate operations. Along with propertyadvisory services, they provide real estate investment and property management services.
Show more
Investment focus
  • Health Care, Life Science, Clinical Trials
  • Series A
  • France
Portfolio highlights
  • DocCity — DocCity LifeSciences creates and provides outstanding spaces to house cutting-edge healthcare businesses. DocCity provides clinicians with state-of-the-art, fully furnished health spaces with roomy, well-lit, and digitally equipped consultation rooms and reception areas.
Earlybird Venture Capital VC Fund · Berlin, Berlin, Germany · 35 investments in the past 12 months
Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. With EUR 2 billion under management,eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Series A, Seed, Series B
  • Germany, United States, United Kingdom
Portfolio highlights
  • GEMMABio — GEMMABio, a new therapeutics company, will serve as the research and innovation arm to speed the research of and global access to life-changing advanced therapies for those living with rare diseases.
  • Upvest — Upvest empowers financial institutions to offer investment products in their app with a modular, scalable, and accessible API. Upvest brings together everything that’s required to offer a broad range of investment products on the website and app. They are connected to the world’s leading asset providers and exchanges to provide the bestinvestments, at the best prices and execution speed.
  • Briefcase — Briefcase automates the legwork in accounting so you can focus on growing your practice
Afone Participations VC Fund · Paris, Ile-de-France, France
Afone Participations is a telecommunications and electronic payments company.
Show more
Investment focus
  • Software, Compliance, Life Science
  • Series A
  • France
Portfolio highlights
  • BMI System — BMI System is a management software editor for the pharmaceutical, medical, and cosmetics industries The company exports its software packages to Europe and America. With the NAYA Compliance application it has established itself as the leading French company for regulatory compliance software for the pharmaceutical industry.
Investors by industry
Investors by country
VC (Venture Capital) Funds in France by industry